Mitapivat improves clinical outcomes in patients with non-transfusion dependent thalassemia
1. Hemoglobin response was significantly greater in the treatment group compared to placebo. 2. Majority of adverse events were mild ...
Tag: α-thalassemia
Mitapivat may improve anemia in adults with non-transfusion dependent α- and β-thalassemia
1. 80% of patients receiving mitapivat showed hemoglobin response at 12 weeks. 2. Markers of hemolysis, such as bilirubin and ...
